Project 2: needs approval from authorities
Working title: “AGEART” (derived from HRT)
Therapeutic Area: Gynecology – Hormone Replacement Therapy (HRT)
Application Form: Tablet, coated Tablet, Capsule, Drinking solution
Route of Administration: Oral
Probability of Realization: Medium to High
Daily 8-PN dose (mg): 50mg (best guess)
Scientific Basis: 8-PN is an orally active estrogen, the problem is to find a dose that does not need to be counteracted by a progestin but has inhibitory effects on bone resorption and suppresses other symptoms in menopause (hot flashes, mood disturbances etc.)
Time to Market (best guess): 4-5 years